Craif key facts
as of Oct 2026- Provider of exosome-based liquid biopsy tests intended to provide accurate and painless early cancer detection.
- Craif is valued at approximately $75.0M as of Oct 2026 (last reported valuation).
- It has raised $42.5M; the latest was Later Stage VC ($22.0M) in Apr 2025.
- Notable investors include Plug and Play Tech Center, MedTech Innovator, Global Brain, Founders Fund, ANRI — 33 tracked in total.
- Status: Privately Held (backing).
Craif's last reported valuation, Apr 2022. Nothing priced has surfaced since.
- ·The complete investor list: 33 names
- ·Watch Craif: the Monday email on marks, rounds and moves
Craif funding rounds
No funding rounds for Craif are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Craif
33+Craif valuation
Craif's last reported valuation was $75 million in Apr 2022. No priced round, secondary trade or fund mark has surfaced since.
Craif investors
33 investors are on record for Craif, including Plug and Play Tech Center, MedTech Innovator, Global Brain and Founders Fund. By type, the record holds 4 venture capital firms and 1 asset manager.
About Craif
Provider of exosome-based liquid biopsy tests intended to provide accurate and painless early cancer detection. The company's bio-platform encapsulates ribonucleic acid and relates to physiological conditions like disease status, enabling research institutions to distinguish cancer from non-cancer samples with high sensitivity and specificity in two cancer types.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2018
- Employees
- 73
- Website
- craif.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.